Autolus Therapeutics (AUTL) Liabilities and Shareholders Equity (2017 - 2025)

Autolus Therapeutics (AUTL) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $589.1 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 24.74% year-over-year to $589.1 million; the trailing twelve-month figure through Dec 2025 stood at $2.7 billion (down 19.22% YoY), and the FY2025 full-year result was $589.1 million, down 24.74% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $589.1 million, down from $661.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $901.4 million in Q1 2024 and bottomed at $263.8 million in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $455.5 million (2023), against an average of $529.5 million.
• The widest annual swing landed in 2024, when Liabilities and Shareholders Equity surged 108.51%; it then slipped 24.74% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $405.6 million in 2021, then advanced by 20.89% to $490.3 million in 2022, then retreated by 23.43% to $375.4 million in 2023, then jumped by 108.51% to $782.7 million in 2024, then retreated by 24.74% to $589.1 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $589.1 million (Q4 2025), $661.9 million (Q3 2025), and $721.0 million (Q2 2025), per Business Quant data.

Peer Comparison